Literature DB >> 7645533

Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era.

K Kalantar-Zadeh1, B Höffken, H Wünsch, H Fink, M Kleiner, F C Luft.   

Abstract

The purpose of this study was to evaluate the sensitivity and specificity of laboratory methods in the diagnosis of posterythropoietin-era, iron-deficient, chronic renal failure patients. The patient population comprised 25 anemic (hemoglobin < 11 g/dL) patients with creatinine greater than 3 mg/dL; 20 were dialysis patients, two were transplant patients, and three patients had renal failure from other causes. Criteria for study inclusion were as follows: bone marrow iron was the reference standard and was graded 0 to +4, ranging from absent to diffuse homogeneous iron staining; serum ferritin concentration and serum transferrin saturation were tested in terms of sensitivity and specificity. The reference standard indicated that iron deficiency existed in 40% of patients. Neither serum ferritin nor transferrin saturation were completely adequate diagnostic tools. Serum ferritin levels less than 200 ng/dL were 100% specific for the diagnosis but only 41% sensitive. Transferrin saturation of less than 20% was 88% sensitive, but only 63% specific. By excluding patients with hypoproteinemia (transferrin values of < 150 mg/dL), the sensitivity of the test increased to 100% and the specificity to 80%. We conclude that transferrin saturation is an adequate screening tool in anemic chronic renal failure patients, provided that hypoproteinemia is not present. By determining both the serum ferritin concentration and the transferrin saturation, a high sensitivity and specificity can be achieved, even in patients with hypoproteinemia. Furthermore, we believe that on this basis, iron therapy in patients with renal insufficiency can be improved.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7645533     DOI: 10.1016/0272-6386(95)90649-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  27 in total

Review 1.  Considerations and challenges in defining optimal iron utilization in hemodialysis.

Authors:  David M Charytan; Amy Barton Pai; Christopher T Chan; Daniel W Coyne; Adriana M Hung; Csaba P Kovesdy; Steven Fishbane
Journal:  J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 10.121

Review 2.  Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.

Authors:  Bradley A Warady; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2013-09-05       Impact factor: 3.714

3.  The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin.

Authors:  Bruno Watschinger; Hermann Salmhofer; Sabine Horn; Ulrich Neyer; Tatjana Wiesinger; Martin Wiesholzer; Helmut Erb; Christine Jaeger; Margit Hemetsberger; Alexander R Rosenkranz
Journal:  Wien Klin Wochenschr       Date:  2013-01-09       Impact factor: 1.704

4.  A linear relationship between serum high-sensitive C-reactive protein and hemoglobin in hemodialysis patients.

Authors:  Behzad Heidari; Muhammad Reza Fazli; Muhammad Ali Ghazi Misaeid; Parham Heidari; Niloofar Hakimi; Abbas Ali Zeraati
Journal:  Clin Exp Nephrol       Date:  2014-11-08       Impact factor: 2.801

5.  Restless Legs Syndrome in Chronic Kidney Disease: Is Iron or Inflammatory Status To Blame?

Authors:  Sandeep K Riar; Larry A Greenbaum; Donald L Bliwise; Roberta M Leu
Journal:  J Clin Sleep Med       Date:  2019-11-15       Impact factor: 4.062

6.  Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?

Authors:  Simona Stancu; Liliana Bârsan; Ana Stanciu; Gabriel Mircescu
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-17       Impact factor: 8.237

7.  Ferumoxytol for treating iron deficiency anemia in CKD.

Authors:  Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira
Journal:  J Am Soc Nephrol       Date:  2008-06-04       Impact factor: 10.121

8.  Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients.

Authors:  Rachelle Bross; Jennifer Zitterkoph; Juhi Pithia; Deborah Benner; Mehdi Rambod; Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2009-01-09       Impact factor: 3.754

9.  Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients.

Authors:  Lillian A Rocha; Daniela V Barreto; Fellype C Barreto; Cristiane B Dias; Rosa Moysés; Maria Regina R Silva; Luiz A R Moura; Sérgio A Draibe; Vanda Jorgetti; Aluízio B Carvalho; Maria Eugênia F Canziani
Journal:  Clin J Am Soc Nephrol       Date:  2008-10-08       Impact factor: 8.237

10.  Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease.

Authors:  Csaba P Kovesdy; Wilber Estrada; Shahram Ahmadzadeh; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.